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Background: Patients with somatic conditions, such as psoriasis, frequently suffer from high 
burden of their disease in daily life and might benefit from internet-delivered cognitive 
behavioral treatment (ICBT) tailored to their adjustment problems. The aim of this 
multicenter randomized controlled trial was to examine the effects of therapist-guided, 
individually-tailored ICBT in a clinical sample of patients with psoriasis.  
Methods: A total of 131 patients with psoriasis, who were screened for a psychological risk 
profile, were randomized to either care as usual (CAU, n=65) or ICBT in addition to care as 
usual (n=66). Participants filled out standardized self-report questionnaires assessing physical 
and psychological functioning, and impact on daily activities, at baseline, post-assessment, 
and 6-month follow-up.  
Results: In covariate-controlled linear mixed models analyses, significantly larger 
improvements in ICBT compared to CAU were found in the primary outcomes physical 
functioning (p=.03, d=0.36) and impact on daily activities (p=.04, d=0.35), but not in 
psychological functioning (p=.32), up to 6 months after treatment as compared to baseline. In 
explorative analyses, the working alliance measured at the beginning of ICBT treatment 
predicted improved physical (p=.02) and psychological (p<.001) outcomes. 
Conclusions: Results underline the promise of therapist-guided, individually-tailored ICBT to 
improve physical functioning and reduce the impact of psoriasis on daily activities in patients 
with a psychological risk profile. Establishing a good therapeutic relationship early on may be 
an important factor that influences treatment outcomes in personalized ICBT interventions. 
Further research is needed to evaluate ICBT effectiveness in additional samples, and to 
explore its underlying mechanisms.   
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Psoriasis is one of the most common immune-related chronic dermatological conditions [1] 
and is known for its high disease burden in daily life [2]. Patients frequently experience 
problems with mood, distress, and social impairments, in addition to the burden of physical 
symptoms [e.g., 3-6]. These problems may also negatively impact upon skin status, disease 
course, adherence, and dermatological treatment success [7-11]. Patients with a psychological 
profile of elevated levels of distress (an estimated 30 to 40%) are known to be at risk for long-
term adjustment problems [e.g., 3, 12] and might benefit from cognitive behavioral therapy 
(CBT), as it has shown to improve physical and psychological functioning in patients with 
chronic somatic conditions [13-16], including dermatological conditions [17-20]. Over the 
last decade, CBT has increasingly been offered online, which may facilitate intervention 
reach, increase cost-effectiveness and time-efficiency, and reduce possible barriers to follow a 
psychological intervention [e.g., 21, 22]. 
While systematic reviews show favorable effects of Internet-based CBT (ICBT) for 
chronic somatic conditions [e.g., 23-25], research in dermatological conditions is scarce. One 
randomized controlled trial (RCT) showed positive effects of unguided ICBT on anxiety and 
quality of life in patients with psoriasis, but was limited by high dropout rates [26]. Therapist 
guidance may improve adherence [27, 28] and treatment effects [e.g., 29-31], and patients 
tend to prefer guidance in ICBT [22, 32]. Furthermore, ICBT is usually based on standardized 
protocols [e.g., 33], whereas recent findings underline the promise of less studied 
individually-tailored interventions [e.g., 34-36]. 
Despite the promising effects of therapist-guided, individually-tailored ICBT in other 
conditions, its effects have not been examined in dermatological conditions. Possible 
predictors and correlates of treatment outcomes, including the therapeutic relationship [37, 
38] and adherence [39], also remain unexplored in this group. Therefore, this study examined 
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the effectiveness of therapist-guided, individually-tailored ICBT for patients with psoriasis, 
expecting greater improvements in physical and psychological functioning, and reduced 
impact on daily activities, in ICBT compared to care as usual (CAU). In addition, socio-
demographic, disease-related, and treatment-related predictors and correlates of treatment 




Participants and procedure 
Study participants were recruited through outpatient dermatology departments of one 
academic and three non-academic hospitals and through the Dutch Psoriasis Association 
(Figure 1). Inclusion criteria were a diagnosis of psoriasis, age ≥18 years, and a positive 
psychological risk profile (i.e., Impact of chronic Skin Disease on Daily Life [ISDL] score of 
≥5 for anxiety and/or ≥21 on negative mood [40, 41]). Exclusion criteria were psychological 
(i.e., diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders [DSM; 
42]) and/or physical comorbidity interfering with the study protocol, current psychological 
treatment, current photo(chemo)therapy, pregnancy, lack of access to a computer and/or 
internet, and illiteracy.  
 This study had an open-label parallel-group RCT design. An independent person 
randomized participants (allocation ratio: 1:1) using a computerized program that minimized 
on age, gender, educational level, recruitment site, self-assessed disease severity, and 
medication use. Patients were randomized to either care as usual (CAU; i.e., regular 
dermatological care) or ICBT in addition to CAU. A member of the research team informed 
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participants by phone and letter about treatment assignment. ICBT interventions took place 
between July 2010 and October 2014. Measurements were collected between June 2010 and 
April 2015. Study assessments were conducted at baseline, post-treatment (CAU: 6 months 
after baseline), and 6-month follow-up (CAU: 12 months after baseline). The study was 
approved by the regional medical ethics committee, registered in the Dutch Trial Registry 
(NTR2436), and conducted in accordance with the Declaration of Helsinki [43]. All 
participants provided written informed consent.  
 
ICBT intervention  
Patients randomized to the ICBT condition received an internet-based, therapist-guided CBT 
intervention aimed to reduce the impact of psoriasis on daily life, which was based on 
previous evidence-based face-to-face interventions [e.g., 41, 44]. The intervention consisted 
of five flexible treatment modules containing a broad variety of cognitive and behavioral 
techniques, focused on themes that patients often experience problems with: itch, pain, 
fatigue, negative mood, and social relationships. Participants started with two face-to-face 
intake sessions with their therapist (i.e., a psychologist), in which individual treatment goals 
were discussed. Next, patients received a telephone-based instruction of the intervention 
website by a researcher to ensure that they were capable of working with the program from  
home. Patients then started with the individually-tailored ICBT intervention, by logging on to 
the secure intervention website. Choice of treatment modules and individual assignments 
within these modules were determined based on individual patient goals, therapist’s judgment, 
and screening procedures [see also 45]. Patients received personalized written feedback on 
their assignments from their therapist, approximately once a week. Intervention duration and 
content varied between participants, depending on treatment goals, with a mean duration of 25 
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weeks (±12 weeks, range=1-57 weeks). For a more detailed description of ICBT modules, 





Primary and secondary outcomes 
The primary outcome was the impact of psoriasis on daily life, measured on three domains, 
for which total scores were computed (i.e., composite scores: the overall average of 
normalized (z-)scores of the questionnaires included in each domain): 1) Psychological 
functioning, consisting of negative mood [ISDL; 40], anxiety [ISDL; 40], and depressive 
symptoms [Beck Depression Inventory; 46, 47]; 2) Physical functioning, consisting of itch 
[ISDL; 40] and fatigue [Checklist Individual Strength; 48]; and 3) Impact on daily activities, 
consisting of role limitations due to physical health problems and role limitations due to 
emotional problems [RAND-36 Health Status Inventory; 49, 50]. Secondary outcomes 
consisted of clinician-rated [Psoriasis Area and Severity Index; 51] and self-reported disease 
severity [Self-Administered Psoriasis Area and Severity Index; 52], and dermatological 
treatment compliance. 
 
Predictors and correlates of treatment outcome 
Socio-demographic (i.e., age, sex, educational level, and marital status), disease-related (i.e., 
disease severity and duration), and treatment-related variables (i.e., working alliance between 
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patient and ICBT therapist [Working Alliance Inventory - Short form; 53, 54], ICBT 
adherence, website logins) were examined as possible predictors and correlates of treatment 
outcomes. Further measurement details of all study variables can be found in the Online 
Supplementary Methods and Results. 
 
Data analysis 
Baseline characteristics were compared with t-tests and χ
2
-tests. Primary analyses were 
conducted using linear mixed-effects modeling, which has superior qualities with regard to 
missing values [56] and makes use of all available data, making this a full-intention-to-treat 
analysis. Models were fitted with full information maximum likelihood estimation. Between-
group effects at post-treatment and follow-up were analyzed with baseline scores of 
dependent variables as covariates. Time was operationalized as a continuous variable, post-
treatment assessment varied across participants as a result of different intervention length. 
Fixed linear effects of time and condition were included and random effects of intercept. 
Primary analyses were conducted including all variables included in randomization (i.e., age, 
sex, educational level, recruitment site, systemic medication use, etanercept use, and disease 
severity) as covariates [57]. In secondary analyses, results were reported 1) without covariates 
(see Results) and 2) excluding ICBT dropouts/non-starters (see Online Supplementary 
Methods and Results).  
 Between-group Cohen’s d type of effect size was calculated, dividing the difference in 
estimated marginal means of primary analyses of the two groups by their pooled pre-treatment 
SD. Within-group Cohen’s d effect sizes were calculated by dividing the difference in pre- 
and post-assessment means by pre-assessment SDs. Effect sizes of 0.2, 0.5, and 0.8 were 
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considered small, moderate, and large [58]. Unstandardized effect sizes were defined as raw 
mean differences between ICBT and CAU. 
Pearson correlation coefficients were calculated between change in primary outcomes 
(residual gain scores) and selected socio-demographic, disease-related, and treatment-related 
variables [59]. All analyses were conducted in IBM SPSS v21. A power analysis with 80% 
power indicated a sample size of two groups of 65 patients was needed, assuming the effect 
size d=0.50 (α=.05), based on previous ICBT studies for physical and psychological 
conditions [61]. Statistical significance was accepted at p<.05. In explorative analyses 
examining correlates of treatment effects, tendencies towards significant effects (p<.10) were 




Between June 2010 and November 2013, 751 patients were screened and 131 patients were 
randomized to either ICBT (n=65) or CAU (n=66). Means and SDs of selected socio-
demographic and disease-related variables are presented in Table 1 and baseline values on 
primary outcomes and their subcomponents, and secondary outcomes, are presented in Tables 
2 and 3. These values did not differ between groups (p-values ≥.10), with the exception of a 
tendency towards higher levels of fatigue (p=.08) and higher clinician-rated disease severity 
(p=.03) in ICBT compared to CAU. Disease severity was generally mild to moderate, with 
7.6% of patients having severe psoriasis (i.e., PASI >10 [62]). 
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- Insert Table 1 about here - 
 
Attrition 
A total of 73.3% of patients filled out post-treatment measurements and 62.6% completed 6-
month follow-up measurements (see Figure 1). ICBT intervention dropout was 26.2%; 10 
patients did not start treatment (non-starters; 15.4%), 6 patients dropped out during treatment 
(non-completers; 9.2%), and 1 patient (1.5%) died during treatment as a result of comorbidity 
unrelated to the treatment. Reported reasons for ICBT dropout, and differences between 
completers and dropouts, can be found in the Online Supplementary Methods and Results.  
 
- Insert Figure 1 about here - 
 
ICBT treatment satisfaction 
Patients in the ICBT group who filled out post-treatment evaluation questionnaires (n=41) 
were satisfied with the ICBT intervention and gave the overall intervention a mean score of 
7.64 (±1.71) and user-friendliness a 7.72 (±1.32) out of 10. A majority of 85.3% of patients 
would recommend the treatment to a friend or relative with a chronic somatic condition and 
87.7% of patients believed the treatment would have long-term positive effects 
(somewhat/probably/certainly). Sixty percent of patients indicated a preference for internet-
based treatment over other forms of treatment (phone-based: 5.0%, face to face: 27.5%) for 
future treatment, and an additional 7.5% gave internet-based treatment a shared first place 
with one or more other modalities. 
 




Results on primary outcomes and their subcomponents, including effect sizes, are presented in 
Table 2 and Figure 2.  
 
- Insert Table 2 and Figure 2 about here - 
 
Psychological functioning 
In linear mixed models analyses controlling for previously specified covariates, no significant 
differences were found between ICBT and CAU regarding psychological functioning at post-
assessment and 6-month follow-up (p=.32), nor on its subcomponents negative mood, 
anxiety, and depressive symptoms (all p-values ≥.20). The lack of significant main effects of 
time (p-values ≥.22) indicated that these outcomes were stable across post-assessment and 6-
month follow-up. Similar results were obtained in secondary analysis including no other 
covariates than baseline values of the dependent variable (p-values ≥.19).   
 
Physical functioning 
Significantly larger improvements in ICBT compared to CAU were found for physical 
functioning up to 6 months after treatment as compared to baseline (F(1,76.29)=4.60, p=.03, 
d=0.36), with significant effects for fatigue (F(1,74.53)=4.16, p=.04, d=0.37), but not for itch 
(p=.30). These outcomes were stable across post-assessment and 6-month follow-up, with the 
exception of fatigue, which tended to be lower at post-assessment than at 6-month follow-up 
(p=.09). In secondary analysis including no other covariates than baseline values of the 
dependent variable, a tendency towards greater improvement in ICBT compared to CAU was 
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found for fatigue (p=.08) and no significant between-group differences for itch or total 
physical functioning (p-values ≥.16).   
 
Impact on daily activities 
Significantly larger improvements in ICBT compared to CAU were found for impact on daily 
activities up to 6 months after treatment as compared to baseline (F(1,81.48)=4.18, p=.04, 
d=0.35), with significant effects on both subcomponents: role limitations due to emotional 
problems (F(1,132)=4.36, p=.04, d=0.33) and role limitations due to physical health problems 
(F(1,81.99)=4.25, p=.04, d=0.32). The improvements in role limitations due to emotional 
problems at post-assessment were further enlarged at follow-up (p=.047), while other 
outcomes remained stable. In secondary analysis including no other covariates than baseline 
values of the dependent variable, no between-group differences were found (p-values ≥.17). 
 
Disease severity and compliance 
Results on self-reported and clinician-assessed disease severity, and dermatological treatment 
compliance, including effect sizes, are reported in Table 3. No between-group differences 
were found for any of these outcomes, with or without covariates (all p-values ≥.25). 
 
- Insert Table 3 about here - 
 
Within-group improvements  
For primary outcome measures, ICBT within-group improvements were large for physical 
functioning (d=0.81-0.90) and moderate for psychological functioning (d=0.59-0.61) and 
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impact on daily activities (d=0.48-0.51). CAU within-group improvements were small to 
moderate for physical functioning (d=0.30-0.56), psychological functioning (d=0.33-0.47), 
and impact on daily activities (d=0.33-0.43). 
 
Predictors and correlates of treatment effects 
To explore which patients benefitted most from treatment, treatment-related variables (i.e., 
working alliance with the therapist, treatment duration, and ICBT adherence including 
patient-ratings, therapist-ratings, and website logins) were correlated with change in primary 
outcomes. Results indicated that a better working alliance with the therapist at the beginning 
of treatment was associated with greater pre-to-post-assessment improvements in 
psychological (r=-.66, p<.001) and physical (r=-.42, p=.02) functioning, but not with change 
in impact on daily activities (r=.18, p=.34). No significant associations with treatment 
duration or ICBT adherence were found, nor with the socio-demographic and disease-related 




This first trial on the effectiveness of individually-tailored, therapist-guided ICBT for patients 
with psoriasis who had a psychological risk profile indicated that ICBT as an adjunct to care 
as usual had more beneficial effects on physical functioning and the impact of psoriasis on 
daily activities, compared to care as usual alone. When analyzing who benefits most from 
ICBT, the working alliance between patient and therapist measured at the beginning of 
treatment was related to improved physical and psychological outcomes, suggesting that the 
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establishment of a good patient-therapist relationship early on is of considerable importance 
in guided ICBT. 
 Results on primary outcomes showed significantly larger improvements in ICBT 
compared to CAU on physical functioning and impact on daily activities. Effects on physical 
functioning were driven by improvements in fatigue, which is a frequent and disabling 
symptom in many chronic inflammatory conditions [63]. Patients often characterize fatigue as 
one of the most burdensome aspects of their condition [63], which was also reflected in the 
current trial; mean baseline scores were above the cut-off point for extreme fatigue [48], while 
means on other outcomes were comparable to norm groups of healthy individuals. In addition, 
the fatigue module was frequently chosen as preferred treatment module in this trial. ICBT 
patients also improved more on impact on daily activities, indicating that patients who 
received ICBT felt significantly less limited by their physical health and emotional problems 
in performing their work or daily activities than patients who received CAU. 
 In contrast, no significant between-group effects were observed for psychological 
functioning. This is surprising, considering that patients were screened for elevated levels of 
distress and that negative mood was a frequently applied treatment module. Despite 
screening, baseline psychological functioning scores were generally comparable to healthy 
populations, as many patients scored just above cutoff values and 22% of the sample that 
scored above cutoff values at screening did not fulfill these criteria anymore at baseline. As 
meta-analyses suggest that patients with higher distress scores demonstrate larger CBT effects 
[63, 64], distress levels may have been too low for patients to benefit sufficiently from ICBT. 
Low baseline scores were also cited as a reason for the small effects found in a recent meta-
analysis on (I)CBT for long-term conditions (i.e., effect sizes of 0.20-0.21 for anxiety and 
depression [66], comparable to an earlier meta-analysis [24]).  
INTERNET-BASED TREATMENT FOR PSORIASIS 
16 
 
Moderate-to-large ICBT effects were found for primary outcomes and their 
subcomponents, that were comparable to similar tailored face-to-face CBT interventions [e.g., 
41, 67]. However, between-group effect sizes were small, which was explained by larger than 
expected CAU-effects. This may also explain why significant effects for physical functioning 
were found for fatigue but not for itch: post-treatment ICBT effect sizes were similar for itch 
and fatigue, while CAU-effects were moderate for itch and small to non-existent for fatigue. 
As high standards of care are generally associated with greater CAU-effects on physical and 
psychological outcomes [68], the fact that 42% of patients were recruited from a university 
medical center might have played a role in these findings. Timing of participant recruitment 
may have also contributed; patients were often recruited when starting dermatological 
treatment and many patients reported changes in systemic medication during the trial. In 
future research, differential screening procedures may decrease these confounding effects and 
possibly optimize treatment effects, by screening patients who experience elevated distress 
levels despite being on a stable dermatological regimen, for example. 
A better therapeutic relationship (i.e., working alliance) measured early in treatment 
showed moderate to large correlations with improvements in physical and psychological 
outcomes, supporting the relevance of the therapeutic relationship in ICBT. These findings 
are in line with evidence in face-to-face CBT [e.g., 69-71] and extend upon scarce evidence 
from studies on internet-based interventions [38, 72-75]. Associations of early working 
alliance scores with treatment outcome were somewhat higher than those observed in 
previous studies, possibly because the therapeutic relationship is of greater importance in 
highly personalized interventions. Number of logins or treatment length were not associated 
with treatment outcomes, partially corresponding with previous conflicting evidence [e.g., 39, 
76, 77]. While logins and treatment length have advantages in being objective measures, they 
may not adequately reflect interaction with treatment content and user experiences.  
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 Characteristics of this study differed in some important ways from many previously 
conducted ICBT studies. ICBT was compared to CAU in a clinical sample, including 6-month 
follow-up, while most ICBT studies have typically included community-based and self-
referred samples, waiting-list comparisons, and post-treatment data only [summarized in 24]. 
While significant effects were found in this trial, effects were typically small and were not all 
found in secondary analyses that did not include pre-specified covariates. Consistent with our 
findings, recent meta-analytic evidence shows that effects of ICBT are typically smaller in 
studies with a CAU than a waiting-list comparison and in clinical samples than in community-
based samples, and often non-significant on the rare occasion that long-term follow-up results 
are meta-analyzed [78-80], underlining the need for further in-depth research regarding the 
influence of methodological, sample, and intervention characteristics on trial results. 
 Both limitations and strengths of the present study have to be considered. Firstly, 
similar to previous studies [summarized in 24], a substantial proportion of patients did not 
complete ICBT and/or failed to return questionnaires. Attrition rates were higher in ICBT 
than in CAU, in line with previous evidence [81]. While dropout rates were somewhat lower 
than in a study of non-tailored ICBT for psoriasis [26], the fact that they were generally 
comparable to previous studies does not support the often-cited idea that tailored interventions 
are associated with less dropout. However, the majority of dropouts were non-starters and 
therefore not exposed to treatment content. Furthermore, the relatively long ICBT duration 
(i.e., a mean duration of 25 weeks, compared to 8 weeks in many other interventions [e.g., 
24]) may have increased dropout rates, which often increase progressively with intervention 
duration [82]. Lower baseline disease severity was associated with higher ICBT dropout, 
possibly because these patients experienced a lower disease burden and were therefore less 
motivated to adhere to a program aimed to decrease the impact of psoriasis on daily life. Main 
strengths of the current study include the application of a unique individually-tailored and 
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therapist-guided intervention in a target population that is generally underserved when it 
comes to psychological support. Methodological strengths include the multicenter RCT 
design comparing a clinical sample to CAU, including 6-month follow-up. 
To conclude, individually-tailored, therapist-guided ICBT led to significantly greater 
improvements compared to CAU for physical functioning and impact on daily activities in a 
clinical sample of patients with a psychological risk profile. The therapeutic relationship 
showed moderate-to-large associations with better treatment effects, illustrating the 
importance of this relationship in guided ICBT. Results of this trial underline the promise of 
ICBT for dermatological conditions in a clinical setting, which is supported by previous 
studies in other conditions showing that ICBT interventions can be transferred to clinical 
practice with sustained effects and moderate to large effect sizes [83]. Future research should 
focus on the working mechanisms and provide further evidence on how well these 
interventions translate into clinical practice. Furthermore, future research in additional 
samples (e.g., higher levels of distress and disease severity) should extend these findings to be 
able to draw robust conclusions on the effectiveness of individually-tailored, therapist-guided 
psychological interventions for dermatological conditions. 
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Table 1. Baseline socio-demographic and disease-related characteristics of internet-based 






Gender (male) 33 (50.8)  34 (51.5) 
Age (years) 52.69  11.27 (24-73) 53.45  13.81 (19-79) 
Married/ living together 46 (70.8) 53 (80.3) 
Educational level   
   Primary  1 (1.5) 4 (6.1) 
   Secondary  44 (67.7) 43 (65.2) 















Disease duration (years) 18.03  13.76 (0-59)
2










Abbreviations: CAU, care as usual; ICBT, internet-based cognitive behavioral treatment; 
PASI, Psoriasis Area and Severity Index; SAPASI, Self-assessed PASI. 




Due to unequal distribution of PASI and SAPASI scores, transformed variables were used in 
analyses (see Methods section). Untransformed scores are displayed in this table. 
4
Number of patients reporting use of systemic treatment. 
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Table 2. Means and SDs of each measurement point on primary outcome measures (i.e., total scores) and their subcomponents, including results 
of linear mixed models analyses and accompanying effect sizes. 
Measurement ICBT Care as usual Standardized 
effect size  
Unstandardized  
effect size (95% CI) 
Linear mixed  
models 
 Mean SD n Mean SD n   Effect p-value 
 Psychological functioning       
 Total score (composite)       
Pre 0.02 0.87 60 -0.01 0.85 59     
Post -0.51 0.74 44 -0.29 0.92 49   Time .22 
Follow-up -0.49 0.90 37 -0.41 0.84 45 0.17 0.14 (-0.14-0.43) Group .32 
 Negative mood (ISDL)
1
       
Pre 5.29 3.77 60 5.39 3.72 58     
Post 3.69 3.36 44 4.60 3.21 49   Time .35 
Follow-up 3.86 3.65 37 4.11 3.53 45 0.06 0.06 (-0.28-0.40) Group .74 
 Anxiety (ISDL)        
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Pre 21.85 4.61 60 22.10 4.58 60     
Post 19.36 4.37 43 21.02 5.74 48   Time .28 
Follow-up 19.45 5.38 37 20.27 5.03 45 0.24 1.09 (-0.57-2.74) Group .20 
 Depressive symptoms (BDI)       
Pre 12.78 7.50 60 11.50 6.23 58     
Post 8.46 5.34 45 8.89 6.82 49   Time .24 
Follow-up 8.53 6.72 37 8.69 6.36 45 0.15 1.01 (-1.28-3.30) Group .38 
 Physical functioning        
 Total score (composite)       
Pre 0.11 0.73 60 -0.12 0.79 58     
Post -0.55 0.75 43 -0.36 0.73 48   Time .13 
Follow-up -0.48 0.77 37 -0.55 0.68 42 0.36 0.27 (0.02-0.52) Group .03 
 Fatigue (CIS-f)        
Pre 37.70 10.68 60 34.31 10.30 59     
Post 30.77 12.46 44 33.58 9.19 49   Time .09 
Follow-up 31.19 11.65 37 31.40 10.09 44 0.37 3.84 (0.09-7.59) Group .04 
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 Itch (ISDL)         
Pre 9.44 3.50 60 9.06 3.75 59     
Post 7.09 3.51 44 7.44 3.67 49   Time .44 
Follow-up 7.44 3.32 37 6.88 2.97 43 0.17 0.61 (-0.56-1.77) Group .30 
 Impact on daily activities       
 Total score (composite)       
Pre 0.03 0.71 58 -0.04 0.89 57     
Post 0.38 0.55 43 0.25 0.88 46   Time .12 
Follow-up 0.37 0.69 37 0.34 0.79 43 0.35 0.28 (0.01-0.55) Group .04 
 Emotional role functioning (RAND-36)     
Pre 78.16 35.07 58 67.54 39.89 57     
Post 86.36 23.09 44 76.09 38.27 46   Time .05 
Follow-up 87.39 26.47 37 85.61 32.47 44 0.33 12.12 (0.64-23.61) Group .04 
 Physical role functioning (RAND-36)     
Pre 53.02 41.90 58 58.89 43.09 60     
Post 72.09 36.68 43 73.94 40.03 47   Time 1.00 
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Follow-up 70.95 41.04 37 70.45 40.08 44 0.32 13.34 (0.46-26.22) Group .04 
Note. All means and SDs are presented as uncorrected scores. Abbreviations: BDI, Beck Depression Inventory; CI, confidence interval; CIS-f, 
Checklist Individual Strength – fatigue; ICBT, internet-based cognitive behavioral treatment; ISDL, Impact of Skin Disease on Daily Life; 
RAND-36, RAND-36 Health Status Inventory. 
1
Due to unequal distribution of IHDL negative mood, transformed variables were used in analyses (see Methods section). Untransformed scores 
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Table 3. Means and SDs of each measurement point on secondary outcome measures, including results of linear mixed models analyses and 
accompanying effect sizes. 
Measurement ICBT Care as usual Standardized 
effect size  
Unstandardized  
effect size (95% CI) 
Linear mixed  
models 
 Mean SD n Mean SD n   Effect p-value 
 Clinician-assessed disease severity (PASI)
1
     
Pre 5.99 5.61 54 4.20 2.87 56     
Post 5.04 4.59 25 3.79 2.94 42   Time .34 
Follow-up 4.76 3.47 22 3.40 2.63 37 0.02 0.01 (-0.32-0.35) Group .94 
 Self-assessed disease-severity (SAPASI)
1
     
Pre 5.27 3.29 59 4.48 2.41 54     
Post 4.61 5.39 44 3.95 2.26 43   Time 1.00 
Follow-up 4.51 3.32 35 3.75 2.03 42 0.25 0.16 (-0.12-0.45) Group .25 
 Dermatological treatment compliance      
Pre 3.96 1.11 59 4.09 1.03 58     
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Post 4.02 1.21 41 4.02 0.98 44   Time .82 
Follow-up 3.91 1.22 31 3.89 1.20 40 -0.11 -0.12 (-0.52-0.28) Group .55 
Note. All means and SDs are presented as uncorrected scores. Abbreviations: ICBT, internet-based cognitive behavioral treatment; PASI, 
Psoriasis Area and Severity Index; SAPASI, self-assessed PASI. 
1
Due to unequal distribution of PASI and SAPASI scores, transformed variables were used in analyses (see Methods section). Untransformed 
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Figure 1. CONSORT flow diagram of participants. 
Note.
 
CAU, Care as usual; CWZ, Canisius-Wilhelmina Hospital, Nijmegen; ICBT, internet-
based cognitive behavioral treatment; PVN, Dutch Psoriasis Association; RS, Rijnstate 
Hospital, Velp; RUMC, Radboud university medical center, Nijmegen; ZGT, Ziekenhuis 
Groep Twente, Almelo 
 
  











Figure 2. Baseline, post-assessment, and 6-month follow-up scores on primary outcome 
measures (i.e., total scores of psychological functioning (a), physical functioning (b), and 
impact on daily activities (c)) for internet-based cognitive behavioral therapy (ICBT) 
and care as usual (CAU) groups, presented as means ± SEM. Negative scores indicate 
improved psychological and psychological functioning in (a) and (b), and positive scores 
indicate reduced impact on daily activities in (c).  
 
